Short Interest in SAB Biotherapeutics, Inc. (NASDAQ:SABSW) Decreases By 56.7%

SAB Biotherapeutics, Inc. (NASDAQ:SABSW) saw a large decrease in short interest in October. As of October 15th, there was short interest totalling 5,200 shares, a decrease of 56.7% from the September 30th total of 12,000 shares. Based on an average trading volume of 9,800 shares, the short-interest ratio is currently 0.5 days.

SAB Biotherapeutics Stock Performance

Shares of SABSW remained flat at $0.05 during trading hours on Monday. The stock had a trading volume of 12,000 shares, compared to its average volume of 19,373. SAB Biotherapeutics has a 52-week low of $0.01 and a 52-week high of $0.19. The business’s 50 day moving average price is $0.03 and its two-hundred day moving average price is $0.04.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.